Positive Drug Tests Sample Clauses

Positive Drug Tests i. After receiving a confirmed positive, but before verifying that result, the MRO will make all reasonable attempts to contact the Flight Attendant (including, if necessary requesting that the Company’s Drug Enforcement Representative (DER) direct the Flight Attendant to contact the MRO) to discuss the test result.
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
Positive Drug Tests. 1. Identification of any amount or level of any panel of drugs to be tested shall be considered a positive test. Subsequent to a positive primary test, the MRO shall discuss with the employee the test results and other appropriate considerations. If a split sample test is/was conducted and determined to be positive, the MRO shall make a recommendation to the employee to meet with a Substance Abuse Professional no later than seventy-two (72) hours) after the confirmation of the positive split sample results. The employee shall meet with the SAP for an assessment, possible required enrollment in a treatment program, and before being permitted to return to work, successfully pass a return to work duty test. If the employee successfully passes the return to duty test, he/she prior to returning to employment, shall serve a ten
Sample 1Sample 2Sample 3See All (4)
Positive Drug Tests. 1. The following will all be considered positive drug results within the meaning of this policy:
Sample 1Sample 2Sample 3See All (4)
Positive Drug Tests a) First Positive: Ten (10) day unpaid suspension. Successful completion of any program as identified by the Substance Abuse Professional (SAP) and Medical Review Officer (MRO).
Sample 1Sample 2Sample 3
Positive Drug Tests. The following cutoff limits will be used to determine whether initial drug screens and confirmation tests are positive for these drugs and/or their metabolites: Initial Enzyme Confirmatory (GC/MS) Immunoassay lc-ms/ms Substance Level ng/ml Level ng/ml Marijuana 50 15 Cocaine 300 150 Opiates 300 300 PCP 00 00 Xxxxxxxxxxxx 0000 500 Barbiturates 300 200 Benzodiazepines 300 200 Propoxyphene 300 200 Methadone 300 200 Methaqualone 300 300 Oxycodones 100 100 The cutoff levels (EMIT/RIA - GC/MS) for the above drugs are subject to change as recommended by the testing laboratory (after discussion with the Union). When a positive drug test may be the result of use of a prescription drug, the Employee will be required to submit proof of the prescription within forty-eight (48) hours of the request to do so, together with a written statement from the Employee’s or Company’s physician approving the use of the drug during working hours. If the prescription and/or the physician's statement is not submitted within the specified time limit, the Employee will be subject to provisional discharge under this policy.
Sample 1
Positive Drug Tests. 1. Identification of any amount or level of any panel of drugs to be tested shall be considered a positive test. Subsequent to a positive primary test, the MRO shall discuss with the employee the test results and other appropriate considerations. If a split sample test is/was conducted and determined to be positive, the MRO shall make a recommendation to the employee to meet with a Substance Abuse Professional no later than seventy-two (72) hours) after the confirmation of the positive split sample results. The employee shall meet with the SAP for an assessment, possible required enrollment in a treatment program, and before being permitted to return to work, successfully pass a return to work duty test. If the employee successfully passes the return to duty test, he/she prior to returning to employment, shall serve a ten (10) day suspension without pay. Subsequent to returning to work, the employee shall be randomly tested for any amount or level of panel of drugs at least six (6) times during the next twelve (12) months. Positive results for any of the six (6) tests will result in immediate discharge.
Sample 1
Positive Drug Tests. In the event that an employee tests positive (and which is confirmed by retesting if requested by the employee) for any illegal narcotic, that individual will be subject to a 24 – hour (One workday) suspension with pay (such suspension shall be charged first to vacation leave, then to personal leave, then to sick leave), provided that the employee seeks treatment through the Town’s EAP or another counseling or treatment program. If the employee does not seek such treatment, said twenty four (24) hours suspension shall be without pay and shall remain a permanent part of the employee’s records. In the event that the employee appropriately seeks treatment and completes an appropriate program, such suspension shall be removed from the employee’s record. If the employee requires additional treatment beyond the 24 hours, the individual may use sick time, vacation time, or personal leave to cover such time away from the job. The employee will not permitted to return to work until the individual is cleared to return for duty either by a substance abuse professional retained by the Town to administer its Employee Assistance Program, or a qualified substance abuse professional who has seen or treated the individual in an appropriate program. This policy will not apply to probationary employees. If, within a 24-month period following the first positive drug test, an employee tests positive for illegal narcotics, they will be subject to receiving a 30-day suspension without pay, provided, however, that if the employee has accrued vacation leave, personal leave or sick leave, the individual may use such accrued leave to receive pay. The employee will not be permitted to return to work until the individual is cleared to return for duty, after completion of an appropriate drug treatment program, by a substance abuse professional retained by the Town to administer its Employee Assistance Program, a qualified substance abuse professional, or medical review officer. If an employee test positive for an illegal narcotic within a 24-month period after having a second positive test, the employee will be subject to discharge. Any employee who has tested positive a second time for drug use, after a period of 24 months of negative tests, all documentation relative to drug use and treatment will be expunged from their personal file.
Sample 1
AutoNDA by SimpleDocs

Related to Positive Drug Tests

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Product Testing Upon request, Customer shall provide Operator a laboratory report for each Product delivery by Customer or Customer’s supplier. Operator will not be obligated to receive Contaminated Product for throughput across the Berths, nor will Operator be obligated to accept Product that fails to meet the quality specifications set forth in the arrival notice.

  • Product Quality 4.1 The following provisions shall apply to Product after Production:

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials conducted or sponsored by the Company (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are, to the Company’s knowledge, being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is reasonably accurate and complete in all material respects in the context of the experimental set-up and fairly presents the data derived from such studies within the limits of interpretation by people trained in the trade, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”) for the operation of the Company’s business as currently conducted, except as could not be expected, individually or in the aggregate, to have a Material Adverse Effect; neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules and regulations of the Regulatory Agencies, except as could not be expected, individually or in the aggregate, to have a Material Adverse Effect.

Time is Money Join Law Insider Premium to draft better contracts faster.